6. (Amended) Use according to claim 1, characterised in that the glucuronidase inhibitor is used for the stabilisation of metabolically-formed glucuronide conjugates of side-effect-rich active materials in order to reduce their side effects or to introduce a detoxification.

7. (Amended) Use according to claim 1, characterised in that the glucuronidase inhibitor is used combined with a glucuronide conjugate of an inflammation-inhibiting active material to be taken orally in order to protect this in the upper stomach-intestine tract against a cleavage and resorption and to activate in the deeper lying intestinal sections by cleavage for the intestinal local therapy.

8. (Amended) Use according to claim 1 for the improvement of the tissue-specific therapy, characterised in that the glucuronidase inhibitor, in the case of combined use with a glucuronide prodrug, protects this against activation in healthy tissue in the case of maintenance of the activation in the target tissue.

9. (Amended) Use according to claim 1, characterised in that, besides the glucuronidase inhibitor and the glucuronide prodrug, there is used combined beta-glucuronidase bound to tissue-specific substances (e.g. antibodies, proteins, liposomes) in order to increase the activation of the prodrug in the target tissue and to protect the healthy tissue against the activation.--